HUTCHMED (China) Limited (H7T1.F)
- Previous Close
17.40 - Open
17.60 - Bid 16.70 x 50000
- Ask 17.10 x 50000
- Day's Range
17.60 - 17.60 - 52 Week Range
9.65 - 19.10 - Volume
10 - Avg. Volume
3 - Market Cap (intraday)
3.005B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
31.43 - EPS (TTM)
0.56 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
47.39
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
www.hutch-med.com1,988
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: H7T1.F
Performance Overview: H7T1.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: H7T1.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: H7T1.F
Valuation Measures
Market Cap
2.89B
Enterprise Value
2.14B
Trailing P/E
31.47
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.92
Price/Book (mrq)
4.41
Enterprise Value/Revenue
2.55
Enterprise Value/EBITDA
31.82
Financial Highlights
Profitability and Income Statement
Profit Margin
12.03%
Return on Assets (ttm)
0.99%
Return on Equity (ttm)
14.65%
Revenue (ttm)
838M
Net Income Avi to Common (ttm)
100.78M
Diluted EPS (ttm)
0.56
Balance Sheet and Cash Flow
Total Cash (mrq)
889.01M
Total Debt/Equity (mrq)
11.59%
Levered Free Cash Flow (ttm)
39.68M
Research Analysis: H7T1.F
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: H7T1.F
H7T1.F does not have Company Insights